Prostanoids in the treatment of pulmonary arterial hypertension

Baskurt M., Kucukoglu M. S.

ANATOLIAN JOURNAL OF CARDIOLOGY, cilt.10, ss.2-8, 2010 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 10
  • Basım Tarihi: 2010
  • Doi Numarası: 10.5152/akd.2010.123
  • Dergi Adı: ANATOLIAN JOURNAL OF CARDIOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.2-8
  • İstanbul Üniversitesi Adresli: Evet

Özet

Prostacyclin, endothelin-1, and nitric oxide pathways are involved in the pathogenesis of pulmonary arterial hypertension. This devastating disease of the pulmonary vasculature is associated with vasoconstriction, thrombosis and proliferation, and this may be partly due to lack of endogenous prostacyclin secondary to prostacyclin synthase downregulation. Prostanoids (prostacycin analogues) are potent vasodilators and possess antiaggregant, antiinflammatory and antiproliferative properties. The first agent to be approved for the treatment of pulmonary arterial hypertension was epoprostenol. In the last decade other prostanoids (treprostinil, iloprost) has been approved for the treatment of pulmonary arterial hypertension. (Anadolu Kardiyol Derg 2010; 10: Suppl 2; 2-8)